President Donald Trump has nominated Dr. Casey Means, a physician and health tech entrepreneur, as the next U.S. Surgeon General. The announcement, made Wednesday, highlights Means' alignment with Health Secretary Robert F. Kennedy Jr.’s "Make America Healthy Again" initiative.
Dr. Means, 37, co-founded the health technology company Levels, which uses data from continuous glucose monitors to help users understand how their food choices affect metabolic health. She is a strong advocate for using personalized data to drive healthier lifestyles and is widely seen as a rising voice in the preventive health and biohacking movement.
Her brother, Calley Means, was recently appointed as a White House adviser, focusing on food policy reform and addressing corporate influence on national health trends. Together, the Means siblings have been vocal supporters of reshaping American health through nutrition-focused and tech-driven approaches.
Dr. Means will replace Trump’s previous nominee, Dr. Janette Nesheiwat, who the president announced will now serve in a different senior role within the Department of Health and Human Services alongside Secretary Kennedy.
As Surgeon General, Dr. Means would become the nation’s leading spokesperson on public health, responsible for delivering science-based guidance on disease prevention, wellness, and reducing chronic illness. Her nomination is expected to energize health reform advocates who support lifestyle medicine and digital health innovation.
Trump’s pick signals a continued shift toward preventive care and a broader embrace of alternative health strategies that prioritize nutrition, metabolic awareness, and data-driven wellness tools. The nomination must still be confirmed by the Senate.


Merck Nears Acquisition of Cidara Therapeutics at Significant Premium
Trump and Lula Discuss Trade, Sanctions, and Security in “Productive” Phone Call
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
IMF Deputy Dan Katz Visits China as Key Economic Review Nears
Putin Concludes High-Level Talks With Trump Envoy on Ending Ukraine Conflict
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Trump’s Name Appears on U.S. Institute of Peace Ahead of Rwanda–Congo Deal Signing
UN General Assembly Demands Russia Return Ukrainian Children Amid Ongoing Conflict
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link
Trump Pardons Former Honduran President Juan Orlando Hernández in Controversial Move
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez
UN Chief Says Gaza Operation “Fundamentally Wrong” as Concerns Over War Crimes Grow 



